Not available
Quote | Astellas Pharma Inc. ADR (OTCMKTS:ALPMY)
Last: | $9.54 |
---|---|
Change Percent: | -1.27% |
Open: | $9.59 |
Close: | $9.54 |
High: | $9.645 |
Low: | $9.51 |
Volume: | 500,591 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Astellas Pharma Inc. ADR (OTCMKTS:ALPMY)
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
2024-04-25 03:54:46 ET More on Astellas Pharma: Pfizer, Astellas first-line bladder cancer therapy accepted for review in China Astellas collaborates with Mass General Brigham for translational medicine Historical earnings data for Astellas Pharma Read the ...
Message Board Posts | Astellas Pharma Inc. ADR (OTCMKTS:ALPMY)
Subject | By | Source | When |
---|---|---|---|
$ALPMY Lets go go go go... Up up and away we go. | SPORT19 | investorshub | 07/02/2023 2:22:09 PM |
bears and bulls | jtrenee89 | investorshub | 07/01/2023 10:34:52 PM |
Thoughts on where this is headed? | rdfdr1 | investorshub | 06/29/2023 4:31:26 PM |
bears and bulls | Sam0 | investorshub | 06/27/2023 3:56:52 AM |
$ALPMY and the shorts continue | johnsyn | investorshub | 06/22/2023 2:00:01 PM |
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting PR Newswire XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurr...
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK...